In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as GeneBioTech Ltd has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
KOSDAQ:A086060 - Analysts future estimates and past financials data (KRW Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2026
89,438
3,589
3,043
6,308
N/A
12/31/2025
90,789
3,789
3,855
7,614
N/A
9/30/2025
92,278
3,682
1,424
5,651
N/A
6/30/2025
88,457
3,598
-1,399
2,970
N/A
3/31/2025
85,654
2,930
-1,691
55
N/A
12/31/2024
82,959
2,865
-1,647
-464
N/A
9/30/2024
80,499
2,551
1,361
2,149
N/A
6/30/2024
80,028
2,426
1,546
2,069
N/A
3/31/2024
80,266
2,605
4,949
5,579
N/A
12/31/2023
79,477
2,591
6,602
7,369
N/A
9/30/2023
82,466
3,594
2,856
3,978
N/A
6/30/2023
84,897
2,600
2,040
3,073
N/A
3/31/2023
83,007
1,846
-951
410
N/A
12/31/2022
82,759
1,523
-4,853
-3,679
N/A
9/30/2022
78,270
316
-5,808
-4,599
N/A
6/30/2022
71,338
415
-4,488
-3,132
N/A
3/31/2022
68,923
338
-6,385
-5,093
N/A
12/31/2021
62,814
-484
-5,828
-2,713
N/A
9/30/2021
55,601
-486
-1,432
1,636
N/A
6/30/2021
56,974
189
-1,607
2,565
N/A
3/31/2021
58,137
103
-2,200
1,900
N/A
12/31/2020
59,119
1,029
-1,803
2,492
N/A
9/30/2020
62,309
905
-4,510
457
N/A
6/30/2020
59,849
493
-6,388
-2,115
N/A
3/31/2020
58,482
1,042
-4,847
-392
N/A
12/31/2019
58,245
847
N/A
-2,682
N/A
9/30/2019
59,572
797
N/A
-2,634
N/A
6/30/2019
59,637
1,386
N/A
671
N/A
3/31/2019
60,224
2,378
N/A
1,769
N/A
12/31/2018
62,809
2,683
N/A
5,955
N/A
9/30/2018
60,961
1,702
N/A
4,013
N/A
6/30/2018
60,652
1,838
N/A
847
N/A
3/31/2018
58,785
2,309
N/A
4,593
N/A
12/31/2017
55,534
2,089
N/A
1,132
N/A
9/30/2017
56,241
3,934
N/A
3,453
N/A
6/30/2017
56,099
3,429
N/A
3,703
N/A
3/31/2017
55,262
2,402
N/A
3,136
N/A
12/31/2016
55,632
2,734
N/A
5,312
N/A
9/30/2016
54,845
2,163
N/A
4,537
N/A
6/30/2016
55,280
2,393
N/A
5,539
N/A
3/31/2016
54,410
2,235
N/A
2,549
N/A
12/31/2015
52,256
1,712
N/A
2,606
N/A
9/30/2015
51,990
1,635
N/A
1,901
N/A
6/30/2015
51,126
1,404
N/A
4,072
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A086060's forecast earnings growth is above the savings rate (3.1%).
Earnings vs Market: Insufficient data to determine if A086060's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A086060's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A086060's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A086060's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A086060's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/18 09:18
End of Day Share Price
2026/06/18 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeneBioTech Co. ,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.